vs
Aclarion, Inc.（ACON）与Celcuity Inc.（CELC）财务数据对比。点击上方公司名可切换其他公司
Aclarion, Inc.是一家专注于慢性下背痛诊疗的医疗科技企业，核心产品基于专利磁共振波谱技术，可精准识别患者的疼痛性椎间盘，服务美国市场的医疗机构与患者，业务覆盖慢性疼痛管理、脊柱护理两大核心领域。
Celcuity Inc.是一家临床阶段生物技术企业，专注于肿瘤学领域，通过专属功能性细胞分析技术开发个性化癌症治疗方案，致力于满足难治性实体瘤患者未被覆盖的医疗需求，主要运营范围覆盖美国及全球生物制药合作网络。
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收
ACON
CELC
| Q4 25 | $18.5K | — | ||
| Q3 25 | $18.9K | — | ||
| Q2 25 | $19.3K | — | ||
| Q1 25 | $19.0K | — | ||
| Q4 24 | $10.2K | — | ||
| Q3 24 | $14.4K | — | ||
| Q2 24 | $11.0K | — | ||
| Q1 24 | $10.1K | — |
净利润ACONCELC
| Q4 25 | $-1.9M | — | ||
| Q3 25 | $-1.7M | — | ||
| Q2 25 | $-1.6M | — | ||
| Q1 25 | $-2.0M | — | ||
| Q4 24 | $-2.0M | — | ||
| Q3 24 | $-1.4M | — | ||
| Q2 24 | $-1.2M | — | ||
| Q1 24 | $-2.4M | — |
毛利率ACONCELC
| Q4 25 | 9.7% | — | ||
| Q3 25 | 23.2% | — | ||
| Q2 25 | 26.6% | — | ||
| Q1 25 | -23.6% | — | ||
| Q4 24 | -100.9% | — | ||
| Q3 24 | -48.1% | — | ||
| Q2 24 | -112.3% | — | ||
| Q1 24 | -92.6% | — |
营业利润率ACONCELC
| Q4 25 | -10785.8% | — | ||
| Q3 25 | -9666.2% | — | ||
| Q2 25 | -8988.6% | — | ||
| Q1 25 | -7856.0% | — | ||
| Q4 24 | -17652.7% | — | ||
| Q3 24 | -8995.3% | — | ||
| Q2 24 | -10350.6% | — | ||
| Q1 24 | -12609.3% | — |
净利率ACONCELC
| Q4 25 | -10223.7% | — | ||
| Q3 25 | -9008.0% | — | ||
| Q2 25 | -8285.9% | — | ||
| Q1 25 | -10728.4% | — | ||
| Q4 24 | -19444.6% | — | ||
| Q3 24 | -9482.7% | — | ||
| Q2 24 | -11285.0% | — | ||
| Q1 24 | -23720.6% | — |
每股收益（稀释后）ACONCELC
| Q4 25 | $1.39 | — | ||
| Q3 25 | $-2.93 | — | ||
| Q2 25 | $-2.75 | — | ||
| Q1 25 | $-9.32 | — | ||
| Q4 24 | $-809.36 | — | ||
| Q3 24 | $-1321.49 | — | ||
| Q2 24 | $-1362.83 | — | ||
| Q1 24 | $-3985.22 | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
